Signs and Symptoms
Think Vaginal Atrophy...
If your postmenopausal patient is suffering
If your postmenopausal patient is suffering
from any of these urinary symptoms3,4,5,6,7
Signs and symptoms may begin to bother patients during the years leading up to menopause, or they may not become a problem until several years into menopause. Although the condition is common, not all menopausal women experience VA. Regular sexual activity increases blood flow which can help to maintain healthy vaginal tissues.8
Imvaggis aligns with menopause recommendations to use the lowest effective dose for treatment of vaginal atrophy.9
NICE guidance states that vaginal oestrogen can be continued for as long as needed to relieve symptoms.4
Imvaggis is indicated for the treatment of vaginal symptoms associated with oestrogen deficiency and not for the treatment of urinary infections or conditions.2
It is important that treatment is started early, if possible, to reduce any irreversible changes occurring.5
Vaginal Atrophy is under-diagnosed and under-treated.3
The prevalence of vaginal atrophy symptoms in postmenopausal women is over 50%.3
References
1. Griesser H, et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas. 2012;71(4):360-368 2. Imvaggis (estriol) 0.03mg Summary of Product Characteristics. Available from https://www.medicines.ie/medicines/imvaggis-0-03-mg-pessary-34870/spc#tabs Last accessed September 2022 3. Nappi RE, et al. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol. 2016;32(8):602-606 4. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. Managing Menopause. Available from https://cks.nice.org.uk/topics/menopause/management/managing-the-menopause/ Last accessed: September 2022 5. Primary Care Women’s Health Forum. Guidance on Diagnosis and Management of Urogenital Atrophy or Genitourinary Syndrome of the Menopause (GSM). Available from https://pcwhf.co.uk/wp-content/uploads/2018/11/GSM-Guideline.pdf. Last accessed: September 2022 6. Parish SJ, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437-447. 7. Erekson EA, et al. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013;20(9):973-979 8. Mayo Clinic. Vaginal atrophy. Symptoms and causes. Available from https://www.mayoclinic.org/diseases-conditions/vaginal-atrophy/symptoms-causes/syc-20352288 Last accessed: September 2022 9. WHC Fact sheet sheet- HRT doses https://www.womens-health-concern.org/wp-content/uploads/2022/06/27-WHC-FACTSHEET-HRT-Doses-MAY2022-01J.pdf Last accessed: September 2022
ADVERSE EVENT REPORTING
Adverse events and product complaints should be reported. To report an adverse event or product complaint for a Besins Healthcare product, please call Besins Healthcare on 01-4004466 or email pharmacovigilance@besins-healthcare.com. Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting forms and information can be found at www.hpra.ie